STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer ; volume:15 ; number:1 ; day:4 ; month:7 ; year:2015 ; pages:1-13 ; date:12.2015
BMC cancer ; 15, Heft 1 (4.7.2015), 1-13, 12.2015
- Urheber
-
Chibaudel, Benoist
- Beteiligte Personen und Organisationen
-
Bonnetain, Franck
Tournigand, Christophe
de Larauze, Marine Hug
de Gramont, Armand
Laurent-Puig, Pierre
Paget, Jérôme
Hadengue, Alexandra
Notelet, Dominique
Benetkiewicz, Magdalena
André, Thierry
de Gramont, Aimery
SpringerLink (Online service)
- DOI
-
10.1186/s12885-015-1503-7
- URN
-
urn:nbn:de:1111-2016110613119
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chibaudel, Benoist
- Bonnetain, Franck
- Tournigand, Christophe
- de Larauze, Marine Hug
- de Gramont, Armand
- Laurent-Puig, Pierre
- Paget, Jérôme
- Hadengue, Alexandra
- Notelet, Dominique
- Benetkiewicz, Magdalena
- André, Thierry
- de Gramont, Aimery
- SpringerLink (Online service)
Ähnliche Objekte (12)
First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
Vemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group
Controversies in the treatment of RAS wild-type metastatic colorectal cancer
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
The relationship between oncogenic KRas and wild-type Ras activity and signaling
Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study
IGF-1 in autosomal dominant cerebellar ataxia - open-label trial
Effects of practicing yoga on alexisomia: an open-label trial
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
Proteomic characterisation of mutant RAS signalling and oncogene-cooperating activity of wild-type p53
First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
Vemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group
Controversies in the treatment of RAS wild-type metastatic colorectal cancer
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
The relationship between oncogenic KRas and wild-type Ras activity and signaling
Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study
IGF-1 in autosomal dominant cerebellar ataxia - open-label trial
Effects of practicing yoga on alexisomia: an open-label trial
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
Proteomic characterisation of mutant RAS signalling and oncogene-cooperating activity of wild-type p53
First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
Vemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group
Controversies in the treatment of RAS wild-type metastatic colorectal cancer
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
The relationship between oncogenic KRas and wild-type Ras activity and signaling
Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study
IGF-1 in autosomal dominant cerebellar ataxia - open-label trial
Effects of practicing yoga on alexisomia: an open-label trial
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP